International myeloma working group consensus statement regarding the current status of allogeneic stem-cell transplantation for multiple myeloma

Henk Lokhorst; Hermann Einsele; David Vesole; Benedetto Bruno; Jesus San Miguel; Jose A. Pérez-Simon; Nicolaus Kröger; Philippe Moreau; Gosta Gahrton; Cristina Gasparetto; Sergio Giralt; William Bensinger

doi:10.1200/JCO.2010.29.7929

International myeloma working group consensus statement regarding the current status of allogeneic stem-cell transplantation for multiple myeloma

Henk Lokhorst
, Hermann Einsele
, David Vesole
, Benedetto Bruno
, Jesus San Miguel
, Jose A. Pérez-Simon
, Nicolaus Kröger
, Philippe Moreau
, Gosta Gahrton
, Cristina Gasparetto
, Sergio Giralt
, William Bensinger

School of Medicine

Research output: Contribution to journal › Review article › peer-review

148 Scopus citations

Abstract

Purpose: To define consensus statement regarding allogeneic stem-cell transplantation (Allo-SCT) as a treatment option for multiple myeloma (MM) on behalf of International Myeloma Working Group. Patients and Methods: In this review, results from prospective and retrospective studies of Allo-SCT in MM are summarized. Results: Although the introduction of reduced-intensity conditioning (RIC) has lowered the high treatment-related mortality associated with myeloablative conditioning, convincing evidence is lacking that Allo-RIC improves the survival compared with autologous stem-cell transplantation. Conclusion: New strategies are necessary to make Allo-SCT safer and more effective for patients with MM. Until this is achieved, Allo-RIC in myeloma should only be recommended in the context of clinical trials.

Original language	English
Pages (from-to)	4521-4530
Number of pages	10
Journal	Journal of Clinical Oncology
Volume	28
Issue number	29
DOIs	https://doi.org/10.1200/JCO.2010.29.7929
State	Published - 10 Oct 2010

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1200/JCO.2010.29.7929

Cite this

Lokhorst, H., Einsele, H., Vesole, D., Bruno, B., San Miguel, J., Pérez-Simon, J. A., Kröger, N., Moreau, P., Gahrton, G., Gasparetto, C., Giralt, S., & Bensinger, W. (2010). International myeloma working group consensus statement regarding the current status of allogeneic stem-cell transplantation for multiple myeloma. Journal of Clinical Oncology, 28(29), 4521-4530. https://doi.org/10.1200/JCO.2010.29.7929

@article{cf76e5282e254be49da76f3a298d473c,

title = "International myeloma working group consensus statement regarding the current status of allogeneic stem-cell transplantation for multiple myeloma",

abstract = "Purpose: To define consensus statement regarding allogeneic stem-cell transplantation (Allo-SCT) as a treatment option for multiple myeloma (MM) on behalf of International Myeloma Working Group. Patients and Methods: In this review, results from prospective and retrospective studies of Allo-SCT in MM are summarized. Results: Although the introduction of reduced-intensity conditioning (RIC) has lowered the high treatment-related mortality associated with myeloablative conditioning, convincing evidence is lacking that Allo-RIC improves the survival compared with autologous stem-cell transplantation. Conclusion: New strategies are necessary to make Allo-SCT safer and more effective for patients with MM. Until this is achieved, Allo-RIC in myeloma should only be recommended in the context of clinical trials.",

author = "Henk Lokhorst and Hermann Einsele and David Vesole and Benedetto Bruno and \{San Miguel\}, Jesus and P{\'e}rez-Simon, \{Jose A.\} and Nicolaus Kr{\"o}ger and Philippe Moreau and Gosta Gahrton and Cristina Gasparetto and Sergio Giralt and William Bensinger",

year = "2010",

month = oct,

day = "10",

doi = "10.1200/JCO.2010.29.7929",

language = "English",

volume = "28",

pages = "4521--4530",

journal = "Journal of Clinical Oncology",

issn = "0732-183X",

publisher = "Lippincott Williams and Wilkins",

number = "29",

}

Lokhorst, H, Einsele, H, Vesole, D, Bruno, B, San Miguel, J, Pérez-Simon, JA, Kröger, N, Moreau, P, Gahrton, G, Gasparetto, C, Giralt, S & Bensinger, W 2010, 'International myeloma working group consensus statement regarding the current status of allogeneic stem-cell transplantation for multiple myeloma', Journal of Clinical Oncology, vol. 28, no. 29, pp. 4521-4530. https://doi.org/10.1200/JCO.2010.29.7929

TY - JOUR

T1 - International myeloma working group consensus statement regarding the current status of allogeneic stem-cell transplantation for multiple myeloma

AU - Lokhorst, Henk

AU - Einsele, Hermann

AU - Vesole, David

AU - Bruno, Benedetto

AU - San Miguel, Jesus

AU - Pérez-Simon, Jose A.

AU - Kröger, Nicolaus

AU - Moreau, Philippe

AU - Gahrton, Gosta

AU - Gasparetto, Cristina

AU - Giralt, Sergio

AU - Bensinger, William

PY - 2010/10/10

Y1 - 2010/10/10

N2 - Purpose: To define consensus statement regarding allogeneic stem-cell transplantation (Allo-SCT) as a treatment option for multiple myeloma (MM) on behalf of International Myeloma Working Group. Patients and Methods: In this review, results from prospective and retrospective studies of Allo-SCT in MM are summarized. Results: Although the introduction of reduced-intensity conditioning (RIC) has lowered the high treatment-related mortality associated with myeloablative conditioning, convincing evidence is lacking that Allo-RIC improves the survival compared with autologous stem-cell transplantation. Conclusion: New strategies are necessary to make Allo-SCT safer and more effective for patients with MM. Until this is achieved, Allo-RIC in myeloma should only be recommended in the context of clinical trials.

AB - Purpose: To define consensus statement regarding allogeneic stem-cell transplantation (Allo-SCT) as a treatment option for multiple myeloma (MM) on behalf of International Myeloma Working Group. Patients and Methods: In this review, results from prospective and retrospective studies of Allo-SCT in MM are summarized. Results: Although the introduction of reduced-intensity conditioning (RIC) has lowered the high treatment-related mortality associated with myeloablative conditioning, convincing evidence is lacking that Allo-RIC improves the survival compared with autologous stem-cell transplantation. Conclusion: New strategies are necessary to make Allo-SCT safer and more effective for patients with MM. Until this is achieved, Allo-RIC in myeloma should only be recommended in the context of clinical trials.

UR - https://www.scopus.com/pages/publications/78650623731

U2 - 10.1200/JCO.2010.29.7929

DO - 10.1200/JCO.2010.29.7929

M3 - Review article

C2 - 20697091

AN - SCOPUS:78650623731

SN - 0732-183X

VL - 28

SP - 4521

EP - 4530

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

IS - 29

ER -

International myeloma working group consensus statement regarding the current status of allogeneic stem-cell transplantation for multiple myeloma

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this